Investors Press Releases Year All202320222021 Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma Mar 30, 2023 Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Mar 01, 2023 Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock Feb 23, 2023 Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium Jan 17, 2023
Year All202320222021 Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma Mar 30, 2023 Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Mar 01, 2023 Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock Feb 23, 2023 Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium Jan 17, 2023
